Capricor Therapeutics (CAPR) announced that a Type A meeting with the U.S. Food and Drug Administration, FDA, has been scheduled to discuss the regulatory path for its Biologics License Application, BLA, for Deramiocel, the Company’s lead cell therapy candidate for the treatment of cardiomyopathy associated with Duchenne muscular dystrophy, DMD.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CAPR:
- Capricor Therapeutics call volume above normal and directionally bullish
- Biotech stocks rise following Prasad exit from FDA
- Capricor Therapeutics: Strategic Refinement and Optimism for Deramiocel’s FDA Approval
- Largest borrow rate increases among liquid names
- Capricor’s Trial Data Deception Triggers Major Lawsuit